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The etiology and maintenance of inflammatory bowel disease (IBD) is the subject of much speculation.
Iliev et al. (2012) impose a change in our views of the gut microbiome and catapult the fungal ‘‘mycobiome’’
center-stage in the exploration of IBD.The interaction between a host and its
microbiome is essential for health of the
host organism (Figure 1). However, recent
investigations have been mostly limited to
studying commensal bacteria, with fungi
largely being ignored as constituents of
the host microbiota. Indeed, the idiom
‘‘microbiome’’ has become synonymous
with commensal bacteria. Key among
investigations of the interactions between
the microbiome and the host has been
identifying the role played by these
microbes in the etiology and maintenance
of inflammatory bowel disease (IBD). It
has now been established that alterations
in the bacterial population can lead to gut
inflammation (Willing et al., 2010), but the
presence and role of fungi in these pro-
cesses is unknown. Although the pres-
ence of a commensal fungal community
on mucosal surfaces has been posited,
little has been done to investigate the
influence of these microbes on health
and disease and, to date, only an oral
‘‘mycobiome’’ has been characterized
(Ghannoum et al., 2010).
A recent study by Iliev et al. (2012)
identified that a populous gut mycobiome
exists in several mammalian species.
This community showed reactivity with
Dectin-1, the host pattern recognition
receptor (PRR) for b-glucan, and demon-
strated varied morphologies. Genomic
characterization of the murine gut myco-
biome indicated that it is a varied ‘‘multi-
ethnic’’ community of diverse fungal
species. Like any such population, the
mycobiome was not homogenous but,
surprisingly, over 97% of the population
comprised just ten fungal species and
remarkably, a single dimorphic fungus,
Candida tropicalis, constituted over 65%
of the entire population. By comparing
these fungal species to those detected
in mouse food, the authors confirmed
that the vast majority of these fungi areindigenous to the gut, rather than food
passengers. These findings are notable,
as they show that Candida spp. are a
major part of the mammalian gut myco-
biome, although interestingly in humans
it would appear that C. albicans and
C. parapsilosis are the major fungal con-
stituents (Scanlan and Marchesi, 2008).
Indeed, C. albicans is not a natural colo-
nizer of mice, although the reasons for
this are still unclear.
Next, Iliev et al. (2012) addressed the
effects this mycobiome has on general
host health and reason with some justifi-
cation that if gut commensal fungi are
recognized by Dectin-1, then mice defi-
cient in this receptor may show dif-
ferences in susceptibility to IBD. As
predicted, Dectin-1-deficient (Clec7a/)
mice suffered greater severity of symp-
toms in a dextran sulfate sodium (DSS)-
induced colitis model, demonstrat-
ing increased weight loss, histological
changes, and proinflammatory cytokine
production. This was not due to differ-
ences in commensal bacteria between
the wild-type and Clec7a/ mice, as the
microbiota was the same in both strains.
The intriguing question here is whether
this increased sensitivity is driven solely
by Dectin-1 deficiency or by an altered
microbiota Clec7a/ mice, as has been
reported in NLRP6/ mice (Elinav et al.,
2011). To answer this, the authors used
a fecal transplant from Clec7a/ to
wild-type mice, with the recipient animals
showing no increase in sensitivity to DSS
colitis. Thus, the increased sensitivity
appears to be due to the lack of Dectin-1
function rather than an alteredmicrobiota.
The authors next investigated what
happens to the mycobiome during the
course of gut inflammation. It has been
well documented that gut inflammation
drives changes in the gut bacterial popu-
lation (Willing et al., 2010), so the authorsCell Host & Microbeassumed that similar changes may occur
in the mycobiome. As predicted, there
was an overall increase in ‘‘opportu-
nistic pathogenic’’ fungi (Candida, Tricho-
sporon) and a decrease in nonpathogenic
fungi (Saccharomyces). Concurrent with
this shift, there is evidence of fungal inva-
sion of inflamed tissues in DSS-treated
Clec7a/ mice, whereas in DSS-treated
wild-type mice the fungi are restricted to
the lumen, suggesting Dectin-1 plays a
role in preventing fungi from breaching
the mucosal barrier and gaining entry to
the host all-you-can-eat buffet. The notion
that this is a host-mediated event rather
than a change in microbiota gains further
support from the authors’ observation
that gut-conditioned dendritic cells from
Clec7a/ mice are restricted in their
ability to kill C. tropicalis in vitro. Further-
more, gut administration of C. tropicalis
to Clec7a/ mice results in more severe
DSS-induced colitis with all its ancillary
pathology. Wild-type mice showed no
effects beyond the norm. Notably, treat-
ment ofClec7a/mice with an antifungal
drug during colitis reversed these effects.
It will be interesting to see if this effect is
common to all pathogenic, filamentous
fungi and whether all nonpathogenic fungi
are incapable of inducing these re-
sponses, thus identifying if this is a com-
mon fungal effect or specific to Candida
species. Taken together, these data sug-
gest that Dectin-1 deficiency leads to
altered immunity to commensal fungi in
the gut. Further, they indicate the para-
mount importance of epithelial cells and
epithelium integrity in maintaining health,
as it is only when this barrier is perturbed
that Dectin-1 deficiency becomes impor-
tant and affects inflammatory disease
severity.
A key question is whether these obser-
vations in mice equate to a similar role for
Dectin-1 in human disease. To address11, June 14, 2012 ª2012 Elsevier Inc. 551
Figure 1. The Mycobiome and Gut Inflammation
Interactions between fungi in the mycobiome and host cells in the gut affect how inflammatory diseases
progress. Breaches in the epithelial barrier due to localized inflammation allow fungi from the mycobiome
to invade the underlying tissue, exposing them to immune cells. In wild-type gut, this contact triggers
immune recognition of fungi via the Dectin-1 receptor, resulting in activation of antifungal responses
and restriction in fungal growth. In contrast, Dectin-1-deficient (Clec7a/) gut has a reduced ability to
recognize and respond to fungi, allowing them to invade more extensively without restriction. This results
in increased damage leading to increased inflammation, exacerbating the symptoms of inflammatory
bowel disease.
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Previewsthis, the authors compared the sequence
of the human Dectin-1 gene (CLEC7A)
between a group of severe, medically re-
fractive ulcerative colitis (MRUC) patients
and another less severe group (non-
MRUC). In doing so, they identified a
single nucleotide polymorphism (SNP)
associated with MRUC and a two-SNP
haplotype even more strongly associated
with MRUC. Future studies should aim to
determine the effect of these haplotypes
on the functional activity of Dectin-1,
although one could speculate that they
might lead to some loss of functionality.
Given that CLEC7A has not been identi-
fied as an IBD susceptibility gene by any
GWAS study to date, the authors propose
that CLEC7A is a severity gene, with vari-
ants aggravating already-established
disease. This fits the known phenotypes
of Clec7a/ mice, which do not develop
colitis spontaneously but do suffer from
a more severe form of the disease. It will
be interesting in the future to see if intro-
duction of these SNPs into the CLEC7A
gene in mice also results in an increased
severity of IBD.552 Cell Host & Microbe 11, June 14, 2012 ªThese findings are an important step
forward in our understanding of micro-
biome-host interactions. Along with other
studies now being published, they re-
present a substantial shift in our under-
standing of host-microbial interactions
and host-fungal interactions in particular.
Aswe identify more receptors recognizing
fungal moieties, such as Dectin-2 recog-
nition of a-mannans (Saijo et al., 2010),
and identify the cooperation between
these receptors in fungal recognition
(Netea et al., 2006), studies with these
receptors will help to further elucidate
the importance of host-fungal interac-
tions in homeostasis and pathogenesis.
A recent study has already implicated
fungal cell-wall mannoproteins inCandida
glabrata-induced colitis (Jawhara et al.,
2012). It will be interesting to see how
deficiencies in each of these fungal
PRRs affect bowel inflammation, particu-
larly given that the different receptors
activate different ‘‘flavors’’ of immune
response (Gringhuis et al., 2011). Looking
to the future, it remains to be determined
whether the role of these interactions2012 Elsevier Inc.with the host immune system (and epithe-
lial cells) is purely a pathological process
or whether they play a major role in the
homeostasis and immune development
of a host, as is the case for some bacteria.
This is an intriguing possibility given the
filamentous morphology of some fungi,
in common with other gut microbiome
members (notably segmented filamen-
tous bacteria) that are suspected of
‘‘tutoring’’ immune responses (Ivanov and
Littman, 2010). Filamentation may be a
key fungal factor in penetrating the thick,
mucus layer covering the gut epithelial
surface, enabling continued interaction
between the host and these microbes. A
better understanding of how we interact
with our mycobiome and what the conse-
quences of these interactions are may
well lead to a world of new and exciting
possibilities.REFERENCES
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